Year: 2025
Type: article
Study design: Case Report
Abstract: Sarcoidosis is a chronic multisystemic, inflammatory disease characterized by the formation of noncaseating granulomas, with cutaneous involvement in a fraction of patients. Although existing literature reports dupilumab to cause sarcoidosis-like reactions, we present a 57-year-old man with erythrodermic sarcoidosis and atopic dermatitis refractory to numerous systemic medications that later improved with dupilumab. The improvement of his pruritus and cutaneous lesions after dupilumab initiation, followed by worsening after temporary discontinuation, then re-improvement after re-initiation supported dupilumab's therapeutic role. IL-4 and IL-13 stimulate tissue fibrosis and irreversible tissue damage in sarcoidosis, perhaps explaining dupilumab's therapeutic mechanism in this patient's case. For patients with severe sarcoidosis refractory to numerous medications, clinicians should keep in mind dupilumab as a potential option, particularly for those patients with concomitant atopic dermatitis.
Source: Dermatology Online Journal
DOI: 10.25251/btwtbw27
Authors: Sooin Choi, Karan Pandher, David Gao, Henry Lim
Institutions: Michigan State University, Henry Ford Health, Henry Ford Hospital
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $300
OpenAlex ID: W4415489127